Andere talen Lytix Biopharma

Aandelen

LYTIX

NO0010405780

Beurs gesloten - Oslo Bors Andere beurzen 16:45:00 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
5,86 ^NOK	0,00%		+2,45%	+20,58%

25/04	Lytix Biopharma kondigt de goedkeuring aan van de Fase II-studie in vroeg-stadium huidkanker (Melanoom) die een belangrijke commerciële mogelijkheid biedt	CI
10/04	Lytix Biopharma haalt tot 55 miljoen Noorse kronen op via aandelenuitgifte	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Correction in the notice of Annual General Meeting in Lytix Biopharma AS	03/05
Lytix Biopharma AS: Notice of Annual General Meeting on 14 May 2024	30/04
Lytix Biopharma AS: Annual Report for 2023	30/04
Lytix Biopharma AS - Share issue pursuant to board authorisation	26/04
Lytix Biopharma AS - Mandatory notification of trade by Primary Insiders and close associates	25/04
Lytix Biopharma AS - Minutes of extraordinary general meeting and final results of share offering	25/04
Lytix Biopharma announces approval of the Phase II study in early-stage skin cancer (melanoma) representing a significant commercial opportunity	25/04
Lytix Biopharma Announces Approval of the Phase II Study in Early-Stage Skin Cancer Representing A Significant Commercial Opportunity	25/04
Lytix Biopharma AS - Preliminary results in the share offering	24/04
Lytix Biopharma AS - Last day of the Application Period	24/04
Lytix Biopharma : CEO Presentation and Q&A with Redeye AB	22/04
Lytix Biopharma to Raise Up to NOK55 Million via Share Offering	10/04
Lytix Biopharma AS Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Lytix Biopharma AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Lytix Biopharma’s License Partner Finalizes Patient Dosing in Phase 2 Trial of Skin Cancer Therapy	05/01
Lytix Biopharma as Announces Encouraging Results from ATLAS-It-04 Study Published in Oncoimmunology	11/12
Lytix Biopharma AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Lytix Biopharma presents third quarter 2023 results	09/11
Lytix Biopharma presenting at major investor conferences in London and Stockholm in November	08/11
Encouraging preliminary data from Lytix Biopharma's ATLAS-IT-05 study presented at ESMO 2023	23-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Lytix Biopharma

Aandelen

LYTIX

NO0010405780

Andere talen

Filters